OPHTHOTECH

Ophthotech Corp.
Investor Relations Department
Five Vaughn Drive
Suite 106
Princeton, NJ 08540
United States

Visit IR website
Sign-up for email alerts

| NASDAQ: OPHT [1] | |
|---|---|
| Last Trade: | 2.87 |
| Trade Time: | 4:00 PM ET Jun 22, 2017 |
| Change: | 0.00 (0.000%) |
| Day Range | N/A - N/A |
| 52-Week Range | 2.24 - 65.96 |
| Volume | N/A |
| Market Cap. ($M) | 102.890 |
| Shares Out (M) | 35.850 |

[1] The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

## Company Profile

Ophthotech is a biopharmaceutical company specializing in the development of novel therapeutics to treat back of the eye diseases, with a focus on developing innovative therapies for age-related macular degeneration (AMD). Ophthotech's most advanced product candidate, Fovista® anti-PDGF therapy, is in Phase 3 clinical trials for use in combination with anti-VEGF therapy that represents the current standard of care for the treatment of wet AMD. Ophthotech's second product candidate, Zimura®, an inhibitor of complement factor C5, is being developed for the treatment of geographic atrophy, a form of dry AMD.

… (more)

## Stock Performance




## Events [ View all ]

There are no events to display at this time. Please check back later.

## Financials [ View all ]

First Quarter Financial Results

*Feb 28, 2017*
Annual Report (10-K)

*Apr 24, 2017*
Definitive Proxy Statement

*May 3, 2017*
Quarterly Report (10-Q)

*Nov 8, 2016*
Quarterly Report (10-Q)

*Aug 5, 2016*
Quarterly Report (10-Q)

Nasdaq